The global computer-aided drug discovery market size is estimated at USD 4.21 billion in 2024, grew to USD 4.72 billion in 2025 and is predicted to surpass around USD 13.08 billion by 2034, expanding at a CAGR of 12% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Computer-Aided Drug Discovery Market
5.1. COVID-19 Landscape: Computer-Aided Drug Discovery Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Computer-Aided Drug Discovery Market, By Type
8.1. Computer-Aided Drug Discovery Market Revenue and Volume, by Type, 2024-2034
8.1.1 Structure-based Drug Design
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Ligand-based Drug Design
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Sequence-based Approaches
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Computer-Aided Drug Discovery Market, By Therapeutic Area
9.1. Computer-Aided Drug Discovery Market Revenue and Volume, by Therapeutic Area, 2024-2034
9.1.1. Oncology
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Neurology
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Cardiovascular diseases
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Respiratory diseases
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Diabetes
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Computer-Aided Drug Discovery Market, By End User
10.1. Computer-Aided Drug Discovery Market Revenue and Volume, by March, 2024-2034
10.1.1. Pharmaceuticals companies
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Biotechnology companies
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Research Laboratories
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 11. Global Computer-Aided Drug Discovery Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by End User(2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by End User(2021-2034)
Chapter 12. Company Profiles
12.1. Albany Molecular Research Inc. (AMRI)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BOCSCI Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. AstraZeneca
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bioduro-Sundia
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Schrödinger, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Aragen Life Sciences Pvt. Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Charles River Laboratories
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Aris Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Albany Molecular Research Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample